Bronchodilator efficacy of 18 μg once-daily tiotropium inhalation via Discair® versus HandiHaler® in adults with chronic obstructive pulmonary disease: randomized, active-controlled, parallel-group, open-label, Phase IV trial

Bronchodilator Efficacy of a Single-Dose 12/400-µg Formoterol/Budesonide Combination as a Dry Powder for Inhalation Delivered by Discair® in Adult Patients with Moderate-to-Severe Stable COPD: Open-Label, Single-Arm, Phase IV Trial

BACKGROUND AND OBJECTIVES

A patient-friendly and easy-to-use multi-dose dry powder inhaler, Discair^®, has been recently developed. The objective of this study was to evaluate the bronchodilator efficacy of a single-dose 12/400-µg formoterol plus budesonide combination as a dry powder for inhalation delivered by Discair^® in adult patients with moderate-to-severe, stable, chronic obstructive pulmonary disease.

METHODS

A total of 33 male patients with moderate-to-severe, chronic obstructive pulmonary disease were included in this single-arm, open-label, phase IV trial. The primary efficacy parameters were the average maximum change in forced expiratory volume in 1 s (FEV₁, in L) and time to maximum FEV₁ response. Absolute and percent change from baseline in FEV₁ and forced vital capacity, maximum change and time to peak forced vital capacity response were also evaluated.

RESULTS

The mean post-bronchodilator FEV₁ maximum value was significantly higher than the pre-bronchodilator baseline FEV₁ value [1.66 (standard deviation 0.43) vs. 1.32 (standard deviation 0.35), p < 0.001], with an absolute change of 0.34 (standard deviation 0.18) and a percent change of 26.0 (standard deviation 0.14) from baseline to maximum response. The average time to peak FEV₁ response was 3.94 h (standard deviation 2.75), while the standardized area under the response-time curve from 0 to 12 h for FEV₁ was 2.72 (standard deviation 1.84). The FEV₁ and forced vital capacity values recorded at each time point during the 12-h post-bronchodilator period were also significantly higher than the baseline values (p < 0.001 for each).

CONCLUSIONS

Our findings revealed significant changes from baseline in post-bronchodilator peak and average FEV₁ and forced vital capacity responses, indicating bronchodilator efficacy of a single-dose 12/400 µg formoterol plus budesonide dry powder formulation delivered by Discair^® in patients with chronic obstructive pulmonary disease.

TRIAL REGISTRATION

ClinicalTrials.gov Identifier NCT03028701.

Bronchodilator efficacy of tiotropium/formoterol (18/12 µg once daily via a Discair inhaler), tiotropium alone (18 µg by Handihaler) or combined with formoterol (12 µg twice daily by Aerolizer) in adults with moderate-to-severe stable COPD

Objectives: The bronchodilator efficacy of a once-daily fixed-dose combination of tiotropium/formoterol (18/12 µg administered via a dry-powder inhaler, Discair) [TIO/FORM_fixed group] vs a single-dose of tiotropium (18 µg) by Handihaler¹ alone [TIO_mono group], or combined with formoterol 12 µg twice-daily by Aerolizer² [TIO/FORM_bid group] was compared in patients with moderate-to-severe stable COPD.Methods: COPD patients were randomized (28 patients/group) to receive TIO/FORM_fixed, TIO_mono, or TIO/FORM_bid. AUC for the changes in FEV₁ and FVC over a 24-h period; bronchodilator response (100 ml improvement in FEV₁) in the first 30 min; maximum changes in FEV₁ and FVC; and safety data were recorded. The primary endpoint was to confirm the non-inferiority of TIO/FORM_fixed vs TIO/FORM_bid in terms of the AUC for the changes in FEV₁ over a 24-h period.Results: Changes in AUC_0-24h for FEV₁ and FVC were similar for TIO/FORM_fixed and TIO/FORM_bid, and were superior to TIO_mono (p < 0.001). A positive bronchodilator response at 30 min was demonstrated in 50%, 64%, and 71% of patients in the TIO_mono, TIO/FORM_bid, and TIO/FORM_fixed groups, respectively (NS). Maximum FEV₁ and FVC changes were measured as 0.25/0.41 L, 0.32/0.49 L, and 0.37/0.53 L, for TIO_mono, TIO/FORM_bid, and TIO/FORM_fixed, respectively (FEV₁: TIO/FORM_fixed vs TIO_mono, p = 0.0017 and TIO/FORM_fixed vs TIO/FORM_bid, p = 0.4846); no differences were recorded between the combination groups.Conclusions: The 24-h bronchodilator efficacy of TIO/FORM_fixed 18/12 µg once-daily by Discair³ was non-inferior to a combination of tiotropium 18 µg by Handihaler plus formoterol 12 µg twice-daily by Aerolizer, and superior to tiotropium 18 µg monotherapy by Handihaler.